The clinical outsourcing market is growing fast — the global CRO market is on track to reach roughly $92B by 2030, and the FSP segment alone is projected to nearly double to ~$33B by 2032. But that growth hasn’t closed the actual gap many organizations live with day to day.
Small-to-mid biotechs — who are behind an estimated 40% of new FDA drug approvals — often can’t justify a full-time clinical development executive, yet still need senior-level oversight to get a program investor-ready.
Consultancies and CROs running FSP models frequently need flexible surge capacity or regional delivery reach (particularly across Southeast Europe/CEE) that’s slow and expensive to build internally.
That’s the gap Nushev Biotech Advisory is built around — not a fixed-scope engagement, but a model that flexes to how each partner actually wants to work:
- Fractional leadership for biotechs that need senior clinical development oversight, without a full executive hire
- Subcontracted delivery for consultancies and CROs that need regional CRO/CRA coverage, without building it themselves
- Referral and joint go-to-market partnerships for organizations that want to extend reach without adding headcount
Backed by 20+ years across CRO and pharma environments (Novartis, IQVIA, WCG, Advanced Clinical), with long-term experience across the US, UK, and EU, and hands-on regional depth in Serbia, Bosnia & Herzegovina, Montenegro, North Macedonia, and Bulgaria — the reach to support engagements globally, plus the specific markets where partners most often need extra capacity.
If any of this sounds like a gap in how your organization is currently resourced, let’s talk. Happy to share more detail — including my CV — on request.
#ClinicalDevelopment #Biotech #CRO #FSP #LifeSciences #ClinicalTrials